Intest Res Search

CLOSE


Search

  • HOME
  • Search
Inflammatory bowel diseases
Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria
Sadik Saman, Martin Goetz, Judith Wendler, Nisar P. Malek, Jan Wehkamp, Thomas Klag
Intest Res. 2019;17(3):340-348.   Published online May 31, 2019
Full text    PubReader    ePub    Crossref - TDM    PDF    
Close layer
prev next
  • SCImago Journal & Country Rank
  • AOCC 2018
  • CSIBD
  • JSIBD
  • kasid
  • TSIBD
  • CCF
  • PubMed Central
  • PubMed
  • KoreaMed
  • KoMCI
  • Scopus
  • Directory of Open Access Journals (DOAJ)
  • GoogleScholar
  • EBSCO
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • ORCID
  • COPE
  • KOFST
  • TrendMD


ABOUT
ARTICLE & TOPICS
Article Category

Browse all articles >

TOPICS

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
Room 305, Lotte Gold Rose II, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-957-6145    Fax: +82-2-957-6146    E-mail: thekasid@irjournal.org                

Copyright © 2021 by Korean Association for the Study of Intestinal Diseases.

Developed in M2PI

Close layer
prev next